Daria V Babushok, Amy E DeZern, Carlos M de Castro, Zora R Rogers, David Beenhouwer, Michael S Broder, Suzanne R Fanning, Sarah N Gibbs, Rabi Hanna, Jaroslaw P Maciejewski, Bart L Scott, Srinivas K Tantravahi, Marcin W Wlodarski, Irina Yermilov, Bhumika J Patel
{"title":"改良德尔菲小组关于重型再生障碍性贫血管理的共识建议。","authors":"Daria V Babushok, Amy E DeZern, Carlos M de Castro, Zora R Rogers, David Beenhouwer, Michael S Broder, Suzanne R Fanning, Sarah N Gibbs, Rabi Hanna, Jaroslaw P Maciejewski, Bart L Scott, Srinivas K Tantravahi, Marcin W Wlodarski, Irina Yermilov, Bhumika J Patel","doi":"10.1182/bloodadvances.2023011642","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Severe aplastic anemia (SAA) is a rare hematologic condition for which there is no clear management algorithm. A panel of 11 experts on adult and pediatric aplastic anemia was assembled and, using the RAND/University of California, Los Angeles modified Delphi panel method, evaluated >600 varying patient care scenarios to develop clinical recommendations for the initial and subsequent management of patients of all ages with SAA. Here, we present the panel's recommendations to rule out inherited bone marrow failure syndromes, on supportive care before and during first-line therapy, and on first-line (initial management) and second-line (subsequent management) therapy of acquired SAA, focusing on when transplant vs medical therapy is most appropriate. These recommendations represent the consensus of 11 experts informed by published literature and experience. They are intended only as general guidance for experienced clinicians who treat patients with SAA and are in no way intended to supersede individual physician and patient decision making. Current and future research should validate this consensus using clinical data. Once validated, we hope these expert panel recommendations will improve outcomes for patients with SAA.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":null,"pages":null},"PeriodicalIF":7.4000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331724/pdf/","citationCount":"0","resultStr":"{\"title\":\"Modified Delphi panel consensus recommendations for management of severe aplastic anemia.\",\"authors\":\"Daria V Babushok, Amy E DeZern, Carlos M de Castro, Zora R Rogers, David Beenhouwer, Michael S Broder, Suzanne R Fanning, Sarah N Gibbs, Rabi Hanna, Jaroslaw P Maciejewski, Bart L Scott, Srinivas K Tantravahi, Marcin W Wlodarski, Irina Yermilov, Bhumika J Patel\",\"doi\":\"10.1182/bloodadvances.2023011642\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>Severe aplastic anemia (SAA) is a rare hematologic condition for which there is no clear management algorithm. A panel of 11 experts on adult and pediatric aplastic anemia was assembled and, using the RAND/University of California, Los Angeles modified Delphi panel method, evaluated >600 varying patient care scenarios to develop clinical recommendations for the initial and subsequent management of patients of all ages with SAA. Here, we present the panel's recommendations to rule out inherited bone marrow failure syndromes, on supportive care before and during first-line therapy, and on first-line (initial management) and second-line (subsequent management) therapy of acquired SAA, focusing on when transplant vs medical therapy is most appropriate. These recommendations represent the consensus of 11 experts informed by published literature and experience. They are intended only as general guidance for experienced clinicians who treat patients with SAA and are in no way intended to supersede individual physician and patient decision making. Current and future research should validate this consensus using clinical data. Once validated, we hope these expert panel recommendations will improve outcomes for patients with SAA.</p>\",\"PeriodicalId\":9228,\"journal\":{\"name\":\"Blood advances\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2024-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331724/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood advances\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1182/bloodadvances.2023011642\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2023011642","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
重型再生障碍性贫血(SAA)是一种罕见的血液病,目前尚无明确的治疗方案。我们组建了一个由 11 位成人和儿童再生障碍性贫血专家组成的小组,采用兰德/加州大学洛杉矶分校改良的德尔菲小组法,对超过 600 种不同的患者护理方案进行了评估,为各年龄段的 SAA 患者的初始和后续管理制定了临床建议。在此,我们介绍该小组就排除遗传性骨髓衰竭(IBMF)综合征、一线治疗前和治疗过程中的支持性护理、获得性 SAA 的一线(初始管理)和二线(后续管理)治疗提出的建议,重点是何时移植与药物治疗最为合适。这些建议是 11 位专家根据已发表的文献和经验达成的共识。这些建议仅供治疗 SAA 患者的经验丰富的临床医生参考,绝不能取代医生和患者的个人决策。当前和未来的研究应利用临床数据验证这一共识。一旦得到验证,我们希望这些专家小组的建议能够改善 SAA 患者的治疗效果。
Modified Delphi panel consensus recommendations for management of severe aplastic anemia.
Abstract: Severe aplastic anemia (SAA) is a rare hematologic condition for which there is no clear management algorithm. A panel of 11 experts on adult and pediatric aplastic anemia was assembled and, using the RAND/University of California, Los Angeles modified Delphi panel method, evaluated >600 varying patient care scenarios to develop clinical recommendations for the initial and subsequent management of patients of all ages with SAA. Here, we present the panel's recommendations to rule out inherited bone marrow failure syndromes, on supportive care before and during first-line therapy, and on first-line (initial management) and second-line (subsequent management) therapy of acquired SAA, focusing on when transplant vs medical therapy is most appropriate. These recommendations represent the consensus of 11 experts informed by published literature and experience. They are intended only as general guidance for experienced clinicians who treat patients with SAA and are in no way intended to supersede individual physician and patient decision making. Current and future research should validate this consensus using clinical data. Once validated, we hope these expert panel recommendations will improve outcomes for patients with SAA.
期刊介绍:
Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016.
Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.